Know Cancer

or
forgot password

Pharmacogenetics of Mylotarg


N/A
N/A
21 Years
Open (Enrolling)
Both
Leukemia

Thank you

Trial Information

Pharmacogenetics of Mylotarg


OBJECTIVES:

- To analyze candidate-coding polymorphisms in CD33 of DNA samples from children with
newly diagnosed acute myeloid leukemia treated with gemtuzumab ozogamicin on
COG-AAML03P1.

- To determine the association between these polymorphisms and clinical response of
patients treated with this regimen.

OUTLINE: Archived DNA samples are analyzed for candidate polymorphisms in CD33 by PCR-based
sequencing.

Inclusion Criteria


DISEASE CHARACTERISTICS:

- Newly diagnosed acute myeloid leukemia

- Treated with gemtuzumab ozogamicin on COG-AAML03P1

- Genomic DNA samples available

PATIENT CHARACTERISTICS:

- Not specified

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

Type of Study:

Observational

Study Design:

N/A

Outcome Measure:

Association between coding polymorphisms in CD33 with clinical response to gemtuzumab ozogamicin

Safety Issue:

No

Principal Investigator

Jatinder Lamba, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Masonic Cancer Center, University of Minnesota

Authority:

United States: Federal Government

Study ID:

CDR0000671448

NCT ID:

NCT01139320

Start Date:

September 2009

Completion Date:

Related Keywords:

  • Leukemia
  • untreated childhood acute myeloid leukemia and other myeloid malignancies
  • Leukemia
  • Leukemia, Myeloid, Acute
  • Leukemia, Myeloid

Name

Location